Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research and development of Clopidogrel cardiovascular drug, Imatinlb anticancer drug, Donepezil anti-psychotic drug, Entecavir for anti-virus and infectious disease, and Esomeprazole. It also exports its products. The company was formerly known as Kyongbo Chemical Co. Ltd. and changed its name to Kyongbo Pharmaceutical Co., Ltd in March 2002. Kyongbo Pharmaceutical Co., Ltd was founded in 1987 and is headquartered in Asan-si, South Korea.
Research context
Kyongbo Pharmaceutical Co., Ltd appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Kyongbo Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 6.3% above its 200 day moving average.
From a valuation standpoint, the stock is 83.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
Kyongbo Pharmaceutical Co., Ltd's total revenue sank by 0.1% to $49B since the same quarter in the previous year.
Its net income has increased by 118.5% to $337M since the same quarter in the previous year.
Finally, its free cash flow grew by 161.5% to $3B since the same quarter in the previous year.
Based on the above factors, Kyongbo Pharmaceutical Co., Ltd gets an overall score of 4/5.